Compare Global Payments Inc (GPN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Mesoblast Limited — how do they compare? Global Payments Inc trades at $79.3 (market cap $21.40B), while Mesoblast Limited trades at $18.96 (market cap $2.31B). The key difference: Global Payments Inc is far larger — about 9.3× Mesoblast Limited's market cap, and Global Payments Inc pays a 1.28% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GPN | MESO | |
|---|---|---|
Market Cap | $21.40B | $2.31B |
Sector | Industrials | Technology |
52-Week High | $90.01 | $20.96 |
52-Week Low | $62.47 | $11.35 |
Enterprise Value | $39.11B | $2.32B |
Dividend Yield | 1.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $75.89, down 1.25% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company maintains solid cash flow generation ($2.66B operating cash flow in 2025) and recently announced a $0.25 dividend. Despite negative net income margin and ROE, revenue trends show recovery potential with 2026 projections at $8.9B. Analyst consensus remains positive with 58% buy ratings and $81.56 price target.
GPN presents a mixed outlook with strong operational execution offset by profitability challenges. The Worldpay integration and AI-powered POS expansion offer growth catalysts, but margin pressure and rising debt levels pose risks. Current valuation at 28.76 P/E appears reasonable given the company's market position in payment technology, though investors should monitor competitive pressures in the fintech space.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
